Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism

Drug Metabolism and Disposition

Volumn 25, Issue 2, 1997, Pages 256-266

  Fitzsimmons, Michael E ^a   Collins, Jerry M ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CHLORZOXAZONE; CYCLOSPORIN A; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; FLUVOXAMINE; FURAFYLLINE; INDINAVIR; KETOCONAZOLE; MEPHENYTOIN; MIDAZOLAM; PROTEINASE INHIBITOR; QUERCETIN; QUINIDINE; SAQUINAVIR; SULFAPHENAZOLE; TERFENADINE; TROLEANDOMYCIN;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MICROSOME; PRIORITY JOURNAL; SMALL INTESTINE;

ANTI-HIV AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; INTESTINE, SMALL; KETOCONAZOLE; MICROSOMES; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; SAQUINAVIR; TERFENADINE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0031024382     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. V. S. Kitchen, C. Skinner, K. Ariyoshi, E. A. Lane, I. B. Duncan, J. Burckhardt, H. U. Burger, K. Bragman, A. J. Pinching, and J. N. Weber: Safety and activity of saquinavir in HIV infection. Lancet 345, 952-954 (1995).
2. L. Eberle, B. Bechowsky, D. Rose, U. Hauser, K. von-der-Helm, L. Gurtler, and H. Nitschko: Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res. Hum. Retroviruses 11, 671-676 (1995).
3. H. Jacobsen, K. Yasargil, D. L. Winslow, C. Craig, A. Kröhn, I. B. Duncan, and J. Mous: Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206, 527-534 (1995).
4. M. W. McDonnell, E. Hitomi, and F. K. Askari: Identification of bilirubin UDP-GTs in the human alimentary tract in accordance with the gut as a putative metabolic organ. Biochem. Pharmacol. 51, 483-488 (1996).
5. G. M. Pacifici, A. Temellini, M. Castiglioni, C. Alessandro, A. Ducci, and L. Giuliani: Interindividual variability of the human hepatic sulphotransferases. Chem.-Biol. Interact. 92, 219-231 (1994).
6. G. M. Pacifici, M. Eligi, and L. Giuliani: (+) and (-) Terbutaline are sulphated at a higher rate in human intestine than in liver. Eur. J. Clin. Pharmacol. 45, 483-487 (1993).
7. G. M. Pacifici, M. Franchi, C. Bencini, F. Repetti, N. Di-Lascio, and G. B. Muraro: Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica. 18, 849-856 (1988).
8. T. Prueksaritanont, L. M. Gorham, J. H. Hochman, L. O. Tran, and K. P. Vyas: Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in CACO-2 cells. Drug Metab. Dispos. 24, 634-642 (1996).
9. W. H. M. Peters and P. G. Kremers: Cytochrome P450 in the intestinal mucosa of man. Biochem. Pharmacol. 38, 1535-1538 (1989).
10. C. Y. Wu, L. Z. Benet, M. F. Hebert, S. K. Gupta, M. Rowland, D. Y. Gomez, and V. J. Wacher: Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 58, 492-497 (1995).
11. I. R. Webber, W. H. M. Peters, and D. J. Back: Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br. J. Clin. Pharmacol. 33, 661-664 (1992).
12. J. C. Kolars, W. M. Awni, R. Merion, and P. B. Watkins: First pass metabolism of cyclosporin by the gut. Lancet 338, 1488-1490 (1991).
13. K. E. Thummel, D. Oshea, M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, and G. R. Wilkinson: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59, 491-502 (1996).
14. J. T. Backman, K. T. Olkkola, and P. J. Neuvonen: Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 59, 7-13 (1996).
15. D. Y. Gomez, V. J. Wacher, S. J. Tomlanovich, M. F. Hebert, and L. Z. Benet: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 58, 15-19 (1995).
16. M. F. Herbert, J. P. Roberts, T. Prueksaritanont, and L. Z. Benet: Bioavailability of cyclosporin with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52, 453-457 (1992).
17. J. W. Harris, A. Rahman, B. R. Kim, F. P. Guengerich, and J. M. Collins: Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026-4035 (1994).
18. I. H. Segel: Enzymes in "Biochemical Calculations," 2nd ed., pp. 208-266. John Wiley & Sons, New York, 1976.
19. C. Yun, R. A. Okerholm, and F. P. Guengerich: Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Drug Metab. Dispos. 21, 403-409 (1990).
20. M. Jurima-Romet, K. Crawford, T. Cyr, and T. Inaba: Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab. Dispos. 22, 849-857 (1994).
21. K. H. J. Ling, G. A. Leeson, S. D. Burmaster, R. H. Hook, M. K. Reith, and L. K. Cheng: Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab. Dispos. 23, 631-636 (1995).
22. M. Shou, J. Grogan, J. A. Mancewicz, K. W. Krausz, F. J. Gonzalez, H. V. Gelboin, and K. R. Korzekwa: Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33, 6450-6455 (1994).
23. D. A. Smith and B. C. Jones: Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol. 44, 2089-2098 (1992).
24. G. E. Schwab, L. L. Raucy, and E. F. Johnson: Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol. Pharmacol. 33, 493-499 (1988).
25. F. J. Wiebel, L. C. Leutz, L. Diamond, and H. V. Gelboin: Aryl hydrocarbon (benzo(a)pyrene)hydroxylase in microsomes from rat tissues: differential inhibition and stimulation by benzoflavones and organic solvents. Arch. Biochem. Biophys. 144, 78-86 (1971).
26. S. A. Wrighton, W. R. Brian, M. A. Sari, M. Iwasaki, F. P. Guengerich, J. L. Raucy, D. T. Molowa, and M. Vandenbranden: Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207-213 (1990).
27. S. E. Clarke, A. D. Ayrton, and R. J. Chenery: Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24, 517-526 (1994).
28. K. L. Kunze and W. F. Trager: Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6, 649-656 (1993).
29. K. Brosen, E. Skjelbo, B. B. Rasmussen, H. E. Poulsen, and S. Loft: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45, 1211-1214 (1993).
30. J. O. Miners, K. J. Smith, R. A. Robson, M. E. McManus, M. E. Veronese, and D. J. Birkett: Tolbutamide hydroxylation by human liver microsomes: kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 37, 1137-1144 (1988).
31. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. Vandenbranden: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306, 240-245 (1993).
32. K. Brosen, T. Zeugin, and U. A. Meyer: Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Ther. 49, 609-617 (1991).
33. T. Inaba, M. Jurima, W. A. Mahon, and W. Kalow: In vitro inhibition studies of two isozymes of human liver cytochrome P450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab. Dispos. 13, 443-448 (1985).
34. R. Peter, R. Bocker, P. H. Beaune, M. Iwasaki, F. P. Guengerich, and C. S. Yang: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450 IIE1. Chem. Res. Toxicol. 3, 566-573 (1990).
35. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
36. F. P. Guengerich, D. Muller-Enoch, and I. A. Blair: Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30, 287-295 (1986).
37. W. Tassaneeyakul, D. J. Birkett, M. E. Veronese, M. E. Mcmanus, R. H. Tukey, L. C. Quattrochi, H. V. Gelboin, and J. O. Miners: Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265, 401-407 (1993).
38. PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U.S.A. 86, 7696-7700 (1989).
39. Y. Irshaid, R. A. Branch, and A. Adedoyin: Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab. Dispos. 24, 164-171 (1996).
40. M. Chiba, M. Hensleigh, J. A. Nishime, S. K. Balani, and J. H. Lin: Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24, 307-314 (1996).
41. W. Cameron, E. Sun, M. Markowitz, C. Farthing, D. McMahon, D. Poretz, C. Cohen, S. Follansbee, D. Ho, J. Mellors, A. Hsu, G. F. Granneman, R. Maki, M. Salgo, J. Court, and J. Leonard: Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data. Proceeding of the XI International Conference on AIDS, 1996.
42. S. Pohjola-Sintonen, M. Viitasalo, L. Toivonen, and P. Neuvonen: Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur. J. Clin. Pharmacol. 45, 191-193 (1993).
43. P. K. Honig, D. C. Worham, K. Zamani, J. C. Mullin, D. P. Conner, and L. R. Cantilena: The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther. 53, 630-636 (1993).
44. P. K. Honig, R. L. Woosley, K. Zamani, D. P. Conner, and L. R. Cantilena: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther. 52, 231-238 (1992).